Evidence map›Paper›PMID 29383038›Full record

ArticleTherapeutic advances in medical oncology2018

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.

Galatea Kallergi, Eleni-Kyriaki Vetsika, Despoina Aggouraki, Eleni Lagoudaki, Anastasios Koutsopoulos, Filippos Koinis, Panagiotis Katsarlinos, Maria Trypaki, Ippokratis Messaritakis, Christos Stournaras and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Role of circulating tumor cell clusters in breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. ES-SCLC Patients with PD-L1Biomedicines · 2024
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Galatea KallergiDepartment of Biochemistry, University of Crete Medical School, Heraklion, Crete, Greece and Hellenic Oncology Research Group (HORG).
Eleni-Kyriaki VetsikaLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece and Hellenic Oncology Research Group (HORG).
Despoina AggourakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece and Hellenic Oncology Research Group (HORG).
Eleni LagoudakiDepartment of Pathology, University General Hospital of Heraklion, Crete, Greece.
Anastasios KoutsopoulosDepartment of Pathology, University General Hospital of Heraklion, Crete, Greece.
Filippos KoinisDepartment of Medical Oncology, University General Hospital of Heraklion, Crete, Greece.
Panagiotis KatsarlinosLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece and Hellenic Oncology Research Group (HORG).
Maria TrypakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece and Hellenic Oncology Research Group (HORG).
Ippokratis MessaritakisLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece and Hellenic Oncology Research Group (HORG).
Christos StournarasDepartment of Biochemistry, University of Crete Medical School, Heraklion, Crete, Greece.
Vassilis GeorgouliasSchool of Medicine, University of Crete, Crete, Greece; Hellenic Oncology Research Group (HORG).
Athanasios KotsakisLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumor cells (CTCs) could escape from the immune system through the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) axis leading to the development of metastasis. The current study investigated the expression of PD-1/PD-L1 on CTCs isolated from non-small cell lung cancer (NSCLC) patients treated with chemotherapy. PATIENTS AND

methodsCTCs were isolated from 30 chemo-naïve stage IV NSCLC patients before and after front-line chemotherapy using the ISET filtration platform. CTCs were detected by Giemsa and immunofluorescence (IF) staining. Samples were analyzed with the ARIOL system.

resultsGiemsa staining revealed that 28 (93.3%) out of 30 and 9 (81.8%) out of 11 patients had detectable CTCs at baseline and after the third chemotherapy cycle, respectively. Cytokeratin (CK)+/CD45- CTCs by IF could be detected in 17 of 30 (56.7%) patients at baseline and in 8 of 11 (72.7%) after the third chemotherapy cycle. Spearman analysis revealed a significant correlation (

conclusionPD-1(+) and PD-L1(+) CTCs could be detected before and after front-line chemotherapy in patients with metastatic NSCLC. The presence of high PD-1(+) CTC numbers before treatment is associated with a poor patient clinical outcome.

Indexed as

CTCsNSCLCPD-L1/PD-1

Identifiers

PMID29383038
PMCPMC5784570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.